TREANDA® (bendamustine HCl) for Injection is a novel chemotherapeutic agent for chronic lymphocytic leukemia (CLL), a slowly progressing cancer of the blood and bone marrow. The most common type of adult leukemia, CLL affects 15,000 Americans annually. While the exact mechanism of action is unknown, TREANDA destroys cancer cells via two pathways -- by damaging the DNA in cancer cells and by disrupting cell division. TREANDA is the first new agent approved by the FDA for CLL treatment since 2001.
TREANDA Prescribing Information
www.treanda.com

AMRIX® is the first and only once-daily, extended release skeletal muscle relaxant indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. It is available in 15 and 30 mg dosage strengths. AMRIX® is produced with Eurand Diffucaps® technology, which permits once-daily dosing.
AMRIX Prescribing Information
www.amrix.com

PROVIGIL® is the first in a new class of wake-promoting agents. Originally approved for the treatment of excessive daytime sleepiness associated with narcolepsy, today PROVIGIL is the only FDA-approved prescription medicine for treatment of excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome and shift work sleep disorder.
PROVIGIL Prescribing Information
www.provigil.com

FENTORA® is the first and only buccal tablet indicated for the management of breakthrough pain in opioid-tolerant patients with cancer, and the first tablet formulation of fentanyl approved for any use. Its proprietary OraVescent® drug delivery system was developed by Cephalon subsidiary CIMA LABS.
FENTORA Prescribing Information
www.fentora.com

The first and only once-monthly injectable medication for the treatment of alcohol dependence. VIVITROL® is indicated for the treatment of alcohol dependence in patients who are able to abstain from alcohol in an outpatient setting prior to treatment initiation. Patients should not be actively drinking at the time of initial VIVITROL administration. VIVITROL should be part of a comprehensive management program that includes psychosocial support.
VIVITROL Prescribing Information
www.vivitrol.com

TRISENOX® is a highly effective therapy for first and subsequent relapse in acute promyelocytic leukemia (APL). TRISENOX is indicated for induction of remission and consolidation in patients with acute promyelocytic leukemia (APL) who are refractory to, or have relapsed from, retinoid and anthracycline chemotherapy, and whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression.
TRISENOX Prescribing Information
www.trisenox.com

ACTIQ®, a medicated lozenge on a handle, was the first prescription medication in the world approved for the treatment of breakthrough pain in opioid-tolerant cancer patients.
ACTIQ Prescribing Information
www.actiq.com

The first and only FDA-approved SGRI, or selective GABA reuptake inhibitor, GABITRIL® is indicated throughout much of the world as adjunct therapy for treatment of partial seizures associated with epilepsy.
GABITRIL Prescribing Information
www.gabitril.com

NUVIGIL™ (armodafinil) Tablets [C-IV] is the single-isomer formulation of modafinil, the active ingredient in PROVIGIL, a non-amphetamine wake-promoting agent for the treatment of excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome, narcolepsy, and shift work sleep disorder. NUVIGIL was approved by the FDA in 2007 and a comprehensive clinical development program is in progress. The company plans a commercial launch once additional clinical data has been amassed.
NUVIGIL Prescribing Information